Ovarian cancer is a drug-sensitive disease, yet most patients still succumb after initial response. Experimental approaches to this disease include the discovery of new drugs, including taxol and ifosfamide; evaluation of candidate drugs such as tetraplatin and topotecan; and approaches to overcome intrinsic and/or acquired resistance. The latter has been addressed by increasing dose-intensity of currently available therapy, developing agents to abrogate dose-limiting toxicity, and by attempts to interfere with mechanisms of resistance.